Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer

Xu, Chengwei; Ma, Xiao; Zhang, Yuan; Pang, Li; Shengjiang, Wang; Yu, Chao; Wang, Yunshan

doi:10.1097/mbc.0b013e3283610381

Cited by 7 publications

(10 citation statements)

References 30 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma TAFI levels have been reported to be elevated in several disease conditions, including acute pancreatitis, type 2 diabetes, rheumatoid arthritis, coronary heart disease, deep venous thrombosis and neoplastic diseases (3,(6)(7)(8)(9)14). In addition, several reports suggested alterations in the TAFI levels in IBD, in which the degree of intestinal inflammation and changes in the TAFI levels appears to be correlated (15,16).…”

Section: Discussionmentioning

confidence: 99%

Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

et al. 2016

View full text Add to dashboard Cite

Objective Patients with ulcerative colitis (UC) are at an increased risk for thromboembolic events, particularly in patients with extensive and active disease. To date, a few studies have been published on the role of thrombin-activatable fibrinolysis inhibitor (TAFI) in UC. However, there are no reports in the literature investigating the effect of UC treatment on plasma TAFI levels. Methods The plasma TAFI antigen levels were quantitatively determined using ELISA kits for 20 UC patients at activation and remission, along with 17 healthy controls. The association between the TAFI levels and inflammatory markers was assessed to determine UC activation. To predict and determine the activation of UC, the Truelove-Witts index and the endoscopic activation index (EAI) were used for each subject. Results The plasma TAFI levels were higher in UC patients at activation of the disease compared with the remission state and in healthy controls. Spearman's correlation analyses revealed that the WBC (r: 0.586, p< 0.001), hsCRP (r: 0.593, p<0.001) and EAI (r: 0.721, p<0.001) were significantly correlated with the TAFI levels. The overall accuracy of TAFI in determining UC activation was 82.5% with a sensitivity, specificity, NPV and PPV of 80%, 85%, 81% and 84.2%, respectively (cut-off value: 156.2% and AUC: 0.879). Conclusion The present study demonstrates that the TAFI levels are elevated in the active state of UC. The assessment of TAFI levels in patients with UC in conjunction with other markers of inflammation may provide additional information for estimating UC activation and severity.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Reports showed that (12,13) databases indicate a high expression of TAFI levels in breast, ovarian and hepatic cancer cell lines. Plasma levels of TAFI are also increased in a number of types of cancers, including BC (10,29). In addition, higher levels of TAFI have been associated with more advanced stages of cancer (30).…”

Section: Discussionmentioning

confidence: 99%

Suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells

Luan

Wang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Human thrombin activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase B2 (CPB2), is a procarboxypeptidase enzyme. The purpose of the present study was to observe the expression of TAFI in breast cancer (BC) and breast cancer cell (BCC) lines and to investigate the effect of TAFI suppression by small interfering (si)RNA gene silencing on invasion and migration of BCC lines. A significant increase in TAFI level was identified by immunohistochemical analysis in BC tissues compared with normal breast tissues. TAFI suppression also inhibited cell viability, invasion and migration ability as demonstrated by MTT, Transwell chamber, and wound scratch assays, respectively (P<0.05). The data suggested that suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells and that TAFI may be a new target for breast cancer therapy.

show abstract

“…Collectively, the results of our present meta-analysis revealed a significant relationship between rs3742264 G>A and rs1926447 C>T polymorphisms and the pathogenesis of CCVDs. Comprehensively speaking, TAFI, also known as carboxypeptidase B2 or carboxypeptidase U, is a zymogen synthesized by the liver and present in the plasma of humans that plays an essential role in fibrinolysis and the activation of plasmin (Chengwei et al, 2013). In general, TAFI can be activated by trypsin-like enzymes such as plasmin, thrombin, or the complex of thrombin/thrombin-thrombomodulin, leading to exposure of the TAFI active site (Ladenvall et al, 2007).…”

Section: Discussionmentioning

confidence: 99%

“…Many SNPs have been identified in the CPB2 gene. Ala147Thr (rs3742264) and Thr325Ile (rs1926447) polymorphisms in the coding region of the CPB2 gene, which correspond to 505G>A and 1040C>T amino acid mutations, respectively, may result in a TAFI isoform with altered anti-fibrinolytic activity; they are the most common polymorphisms in the CPB2 gene and are significantly associated with TAFI plasma antigen levels (Chengwei et al, 2013;Tokgoz et al, 2013). To the best of our knowledge, there are opposing opinions with regards to the relationship between CPB2 gene polymorphisms and susceptibility to CCVDs (Sun et al, 2011;Tokgoz et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. Cardiovascular and cerebrovascular diseases (CCVDs) are common and have high rates of morbidity, mortality, and recurrence. Thrombin-activatable fibrinolysis inhibitor (TAFI) is also known as carboxypeptidase B2 and is encoded by the CPB2 gene; CPB2 polymorphisms have been explored in a variety of studies, but their correlation to the risk of CCVDs remains ambiguous. We examined the hypothesized associations between CPB2 mutations and CCVDs in a general population. We searched, Embase, the Cumulative Index to Nursing and Allied Health Literature, the Science Citation Index, and several Chinese databases without applying any language restrictions. Nine case-control studies were analyzed in the current meta-analysis, and odds ratios (ORs) with their 95% confidence intervals were calculated. The pooled ORs indicated that the CPB2 rs3742264 G>A polymorphism was associated with an increased risk of CCVDs in the allele model (all P values < 0.05). A similar result for the CPB2 rs1926447 C>T polymorphism and CCVDs risk was detected in the allele model (P < 0.05). Ethnicity subgroup analysis implied that the rs3742264 G>A polymorphism was more likely to lead to the development of cerebrovascular disease in Asians (all P values < 0.05), whereas rs1926447 C>T was associated with cardiovascular disease among Africans (all P values < 0.05). These data suggest that the polymorphisms investigated, especially rs3742264 G>A and rs1926447 C>T, have a modest effect on susceptibility to CCVDs.

show abstract

Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer

Cited by 7 publications

References 30 publications

Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

Suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

Contact Info

Product

Resources

About